Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study

Författare

Summary, in English

OBJECTIVE: Our purpose was to study the effects of isradipine, a dihydropyridine calcium channel blocker, on mother and fetus in the treatment of hypertensive disorders of pregnancy. STUDY DESIGN: The investigation was performed as a two-group, parallel, double-blind multicenter study of isradipine versus placebo. Fifty-four women were randomized to treatment with isradipine slow-release capsules given orally 5 mg twice a day and 57 to a placebo group. RESULTS: Isradipine lowered the maternal mean arterial blood pressure effectively in women with nonproteinuric hypertension but did not do so in women with proteinuria at recruitment or appearing during treatment. Blood flow in the umbilical artery and maternal renal and liver function were not influenced by treatment. Isradipine had few side effects and was well tolerated. CONCLUSION: Calcium channel blockade with isradipine is effective for treatment of nonproteinuric hypertension but not in preeclampsia.

Publiceringsår

1995

Språk

Engelska

Sidor

872-878

Publikation/Tidskrift/Serie

American Journal of Obstetrics and Gynecology

Volym

173

Issue

3 Pt 1

Dokumenttyp

Artikel i tidskrift

Förlag

Elsevier

Ämne

  • Obstetrics, Gynecology and Reproductive Medicine

Nyckelord

  • Isradipine
  • pregnancy
  • hypertension
  • preeclampsia
  • drugs
  • treatment

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1097-6868